Radiance Biopharma enters exclusive license for ROR-1 targeted Antibody Drug Conjugate (ADC)

CAR-T Digest - August 2020

19 Feb 2025: Radiance Biopharma enters exclusive license for ROR-1 targeted Antibody Drug Conjugate (ADC)

Radiance Biopharma has signed an exclusive license agreement with CSPC Megalith for the development and commercialization of RB-164 (SYS6005), an ADC targeting ROR-1 in multiple regions, including the USA, Canada, and Europe
ROR-1 is a promising target for cancer therapy due to its high expression in malignancies and low presence in healthy adult cells, making RB-164 a potential breakthrough treatment
The IND application for RB-164 has been approved in China, and CSPC is conducting a Phase 1 clinical trial; Radiance and CSPC will work together to secure FDA approval in the USA
Radiance will pay CSPC $15 million upfront, up to $150 million in milestone payments, and over $1 billion in commercial milestones, along with tiered royalties
Executives from Radiance and CSPC express optimism, seeing RB-164 as a potential best-in-class ADC to address unmet needs in cancer treatment